<DOC>
	<DOCNO>NCT00901654</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response ACE527 .</brief_summary>
	<brief_title>ACE527 Safety Immunogenicity Study</brief_title>
	<detailed_description>The study phase I , single center , double-blind , placebo-controlled dose find clinical study evaluate safety , tolerability immunogenicity live attenuate , oral vaccine ACE527 . The study design evaluate 2 dos ACE527 2 cohort . Each cohort consist approximately 18 subject ( healthy subject ) , approximately 12 receive ACE527 approximately 6 receive placebo . Within cohort , second dose give safety tolerability first dose acceptable . This assessment base evaluation data Day 7 Independent Safety Committee ( ISC ) per write guidance . The first dose cohort administer inpatient stay . Escalation next dose level dependent acceptable safety profile first dose previous dose level , base evaluation safety data Independent Safety Committee ( ISC ) . The decision administer second dose high level also require review safety tolerability second dose low level . The second dose administer outpatient clinic subject observe least 60 minute vaccination prior discharge unit .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age ≥18 ≤50 year . General good health , without clinically significant medical illness , physical examination finding laboratory abnormality , determine Principal Investigator ( PI ) PI consultation medical monitor ( MM ) sponsor . Negative serum pregnancy test screen negative urine pregnancy test immunization female subject childbearing potential . Females childbearing potential must breastfeed must agree use efficacious hormonal barrier method birth control study . Abstinence acceptable . Female subject unable bear child ( e.g . tubal ligation hysterectomy ) must negative pregnancy test . Working food handler , childcare healthcare worker direct patient contact . Have household contact &lt; 2 year old &gt; 80 year old infirm immunocompromised ( reason include corticosteroid therapy , HIV infection , cancer chemotherapy , chronic debilitate disease ) Pregnancy , risk pregnancy , lactation ( female subject ) . Abnormal stool pattern ( few 3 per week 3 per day ) . Regular use laxative , antacid , agent low stomach acidity . Use medication know affect immune function ( e.g. , corticosteroid others ) within 30 day precede first vaccination plan use active study period . ( Topical intraarticular steroid exclude subject ) . Known allergy quinolones , trimethoprimsulfamethoxazole penicillin . Symptoms consistent Traveller 's Diarrhea concurrent travel country ETEC infection endemic ( develop world ) within 2 year prior vaccination . Received vaccination , ingestion , ETEC , cholera toxin , LT toxin within 3 year prior vaccination . Use antibiotic 7 day prior vaccination and/or proton pump inhibitor , H2 blocker , antacid within 48 hour prior vaccination . History diarrhea 7 day prior vaccination ( outpatient diarrhea define ≥ 3 unformed loose stool 24 hour ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Vaccination</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Traveler 's Diarrhea</keyword>
	<keyword>ETEC</keyword>
	<keyword>Enterotoxigenic E. coli</keyword>
</DOC>